Johnson & Johnson’s (NYSE:JNJ) new director comes with a high pedigree, having served terms in the top seats at both the FDA and at the Centers for Medicare & Medicaid Services.
New board member Dr. Mark McClellan was the FDA’s commissioner from 2002 to 2004 and then served as CMS administrator from 2004 to 2006, according to a J&J statement.
"Dr. McClellan has a distinguished record in the public sector as well as a deep understanding and vision for the future of health care," J&J chairman & CEO Alex Gorsky said in prepared remarks. "Mark shares our aspiration to help people live longer, healthier and happier lives and personally is committed to improving health care across the globe."
Adding to McClellan’s list of prestigious titles, the former FDA chief also served on the President’s Council of Economic Advisors from 2001 to 2002 and was deputy assistant secretary of the Treasury for economic policy during President William Clinton’s administration.
Covidien chief joins board at State Street Corp.
Covidien (NYSE:COV) CEO Jose Almeida joined the board of directors at financial services giant State Street Corp. (NYSE:STT), as well as at State Street Bank & Trust Co.
Read more
Former Echo Therapeutics CEO relinquishes board membership
Former Echo Therapeutics (NSDQ:ECTE) president & CEO Dr. Patrick Mooney, who resigned suddenly earlier this year, officially relinquished his position as chairman of the board and member of the board of the directors.
Read more
European medtech lobby’s new chairman comes from Medtronic
Eucomed, a European medical device trade group, elected Medtronic (NYSE:MDT) vice president and EMEA and Canada president Ten Hoedt its new chairman.
Read more
Cardiovascular Research Foundation gets a new CEO
The Cardiovascular Research Foundation named Dr. John Lewin its new chief executive, also adding him to the board of directors. Read more